Navigation Links
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
Date:7/28/2014

DALLAS July 28, 2014 UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

The molecule, SML-8-73-1 (SML), interferes with the KRAS gene, or Kirsten rat sarcoma viral oncogene homolog. The gene produces proteins called K-Ras that influence when cells divide. Mutations in K-Ras can result in normal cells dividing uncontrollably and turning cancerous. These mutations are particularly found in cancers of the lung, pancreas, and colon. In addition, people who have the mutated gene are less responsive to therapy.

Researchers have unsuccessfully tried to develop a drug to inhibit K-Ras for some 30 years.

"RAS proteins including KRAS have not been 'druggable' for many decades despite a lot of effort from academia and industry," said senior author Dr. Kenneth Westover, Assistant Professor of Radiation Oncology and Biochemistry, and a member of UT Southwestern's Harold C. Simmons Cancer Center.

"We are exploring irreversible inhibitors as a solution, which we believe may pave the way for the development of KRAS-targeted compounds with therapeutic potential and perhaps compounds that target other RAS family proteins involved in cancer," Dr. Westover said.

Dr. Westover works as both a clinician as a member of the Lung Radiation Oncology Team at the Simmons Cancer Center, and as a researcher. The Westover laboratory investigates the molecular basis of cancer with an eye toward developing compounds that perturb cancer biology, and therefore have potential to become therapies. Dr. Westover's lab has been particularly targeting KRAS because this gene is the most commonly mutated oncogene in cancer.

Building on previous work, Dr. Westover and fellow investigators used a technique called X-ray crystallography to determine what happens when SML is added to KRAS carrying the G12C mutation, a hallmark of tobacco-associated lung cancer and present in 25,000 of the new cases of lung cancer in the U.S. annually.

Researchers found that SML irreversibly binds to mutated KRAS, making the KRAS G12C inactive. SML competes with molecules that KRAS naturally binds to, called GTP and GDP, and is not removable, even when GTP and GDP are present at very high levels. This attribute is what makes SML an irreversible inhibitor neither GDP nor GTP are able to knock it off and take its place.

The researchers then used a technique called mass spectrometry to determine that SML is not only irreversible, but selective binding only to KRAS and not the roughly 100 other members of the RAS protein family that have very similar structures.

"We believe SML may be the first irreversible and selective inhibitor of KRAS," said Dr. Westover, who was recruited to UT Southwestern with funds from the state-funded Cancer Research and Prevention Institute of Texas. "As a next step, we are improving the SML compound to facilitate studies involving living cancer cells, and eventually animals and humans."


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Study helps compare risks of treatments for early esophageal cancer
2. Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors
3. Potential universal blood test for cancer discovered
4. Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills
5. Lifestyle choices may affect the long-term heart health of childhood cancer survivors
6. Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk
7. Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening
8. Anal, Throat Cancers on the Rise Among Young Adults, Study Finds
9. Scientists test nanoparticle alarm clock to awaken immune systems put to sleep by cancer
10. ACR statement on cancer study regarding patient anxiety from CT lung cancer screening
11. Is Europe putting cancer research at risk?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ Chicago , ... local organizations: North Chicago Animal Control and Friends and Our House of Hope Rescue. ... and trained volunteers who support rescued animals held in the City of North Chicago’s ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher ... year. We would all agree of course–no time of year is a good time ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... 7, 2016 Boehringer Ingelheim today announced ... with unresectable malignant pleural mesothelioma (MPM) met its ... presented at the 17 th IASLC World ... , showed nintedanib plus pemetrexed/cisplatin demonstrated a ... with a significantly improved PFS (9.4 vs 5.7 ...
(Date:12/7/2016)... , December 7, 2016 Today, Stock-Callers.com ... (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ... ), and AveXis Inc. (NASDAQ: AVXS ). From ... fell roughly 37% to reach a level equal to what ... down by approximately 14% for the year, it has still ...
Breaking Medicine Technology: